GLSI - NASDAQ
Greenwich LifeSciences, Inc.
$24.29
-15%Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
At a Glance
Live Snapshotglsi
Account Payables
Last Annual Value
0.00
3-Year CAGR
%
5-Year CAGR
%
10-Year CAGR
%
Greenwich LifeSciences, Inc. Competitors Analysis of Account Payables
| Company | Account Payables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Greenwich LifeSciences, Inc. NASDAQ:GLSI | 0.00 | N/A | N/A | N/A | |
 TuHURA Biosciences, Inc. NASDAQ:HURA | 0.00 | N/A | N/A | N/A | |
 Seer, Inc. NASDAQ:SEER | 5.61M | 60.0% | 8.2% | N/A | |
 Surrozen, Inc. NASDAQ:SRZN | 728.00K | 11.5% | -23.2% | N/A | |
 Acumen Pharmaceuticals, Inc. NASDAQ:ABOS | 554.00K | -26.2% | -12.6% | N/A | |
 Anixa Biosciences, Inc. NASDAQ:ANIX | 165.00K | -7.1% | 3.9% | -7.8% | |
 C4 Therapeutics, Inc. NASDAQ:CCCC | 858.00K | -16.0% | -28.2% | N/A | |
 Cardiff Oncology, Inc. NASDAQ:CRDF | 8.09M | 60.2% | 41.2% | 21.7% | |
 Nuvectis Pharma, Inc. NASDAQ:NVCT | 6.27M | 31.3% | 42.8% | N/A | |
 PepGen Inc. NASDAQ:PEPG | 822.00K | -6.5% | -24.0% | N/A | |
 Opus Genetics, Inc. NASDAQ:IRD | 3.29M | 15.2% | 15.8% | N/A |
Greenwich LifeSciences, Inc. Fair Value Envelope
Related Guides
Continue your GLSI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.